Klarithrin (Clarithromycin)

Clarithromycin binds to the bacterial 50S ribosomal subunit, blocking the translocation step of protein synthesis. This inhibition prevents peptide chain elongation, resulting in a bacteriostatic effect that halts bacterial growth; at higher concentrations it may be bactericidal.

The appropriate dose of Klarithrin is determined by the prescribing healthcare professional based on the specific infection, patient age, renal and hepatic function, and other clinical factors. Dosage regimens vary and should follow the prescriber’s instructions and relevant clinical guidelines.

Safety of clarithromycin during pregnancy and lactation has not been definitively established; it should only be used when the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should evaluate the risk‑benefit profile before prescribing to pregnant or nursing women.

To order Klarithrin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then provide pricing, availability, shipping details and any necessary import documentation.

Klarithrin (clarithromycin) shares the macrolide class’s mechanism of inhibiting bacterial protein synthesis, but it generally offers higher acid stability and better tissue penetration than erythromycin, and a longer half‑life allowing twice‑daily dosing. Compared with azithromycin, clarithromycin has a broader spectrum against certain Gram‑positive organisms but may have more drug‑interaction potential due to CYP3A4 metabolism.

Klarithrin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Klarithrin is administered orally, typically as a tablet or oral suspension, and should be taken with or without food as directed by the prescriber. The full course should be completed even if symptoms improve, to ensure eradication of the infection and reduce resistance risk.

The most serious risks of Klarithrin include severe allergic reactions such as anaphylaxis, QT‑interval prolongation leading to potentially life‑threatening arrhythmias, hepatotoxicity, and Clostridioides difficile‑associated colitis. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Klarithrin should not be used by individuals with a known hypersensitivity to clarithromycin, other macrolides, or any of the product’s excipients. Caution is also advised for patients with pre‑existing QT prolongation, severe hepatic impairment, or those taking medications that strongly interact via CYP3A4, unless a prescriber determines it is appropriate.